Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program
ZUG, SWITZERLAND AND VILNIUS, LITHUANIA, Mar 4, 2025 – (ACN Newswire) – Micreos Pharmaceuticals AG (“Micreos”), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech (“NBT”), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production
ZUG, SWITZERLAND AND VILNIUS, LITHUANIA, Mar 4, 2025 – (ACN Newswire) – Micreos Pharmaceuticals AG (“Micreos”), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech (“NBT”), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos’ biologic therapeutic MEndoB…
Read More
About Author
